A business in context

AURX research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-08 · 8005 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4/A · Ownership change

    Report date 2026-08-27 · 0001437749-26-029257

  2. 4 · Ownership change

    Report date 2026-08-27 · 0001437749-26-029236

  3. 8-K · Current report

    Report date 2026-08-17 · 0001437749-26-028109 · Items 2.02,9.01

  4. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001437749-26-028053

  5. 4 · Ownership change

    Report date 2026-06-29 · 0001437749-26-022670

  6. 4 · Ownership change

    Report date 2026-06-29 · 0001437749-26-022665

  7. 4 · Ownership change

    Report date 2026-06-29 · 0001437749-26-022664

  8. 4 · Ownership change

    Report date 2026-06-29 · 0001437749-26-022662

  9. 4 · Ownership change

    Report date 2026-06-29 · 0001437749-26-022661

  10. 4 · Ownership change

    Report date 2026-06-05 · 0001437749-26-019768

  11. 8-K · Current report

    Report date 2026-05-29 · 0001437749-26-019199 · Items 1.01,2.03,3.02,9.01

  12. 8-K · Current report

    Report date 2026-05-14 · 0001437749-26-017116 · Items 2.02,9.01

  13. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001437749-26-017104

  14. 10-K · Annual report

    Report date 2025-12-31 · 0001437749-26-010360

  15. 8-K · Current report

    Report date 2026-01-21 · 0001437749-26-002078 · Items 1.01,2.03,3.02,9.01

  16. 8-K · Current report

    Report date 2025-12-16 · 0001437749-25-038091 · Items 5.07

  17. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001437749-25-032437

  18. DEF 14A · Proxy statement

    Report date 2025-12-16 · 0001437749-25-032357

  19. 8-K · Current report

    Report date 2025-10-07 · 0001437749-25-030813 · Items 5.02,5.08,8.01

  20. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001437749-25-024043

  21. 8-K · Current report

    Report date 2025-05-14 · 0001437749-25-017214 · Items 1.01

  22. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001437749-25-013653

  23. 10-K · Annual report

    Report date 2024-12-31 · 0001437749-25-010379

  24. SC 13G/A · Ownership disclosure

    0001193805-24-001361

  25. 10-Q · Quarterly report

    Report date 2024-09-30 · 0001437749-24-034325

  26. SC 13G/A · Ownership disclosure

    0001437749-24-031767

  27. 8-K · Current report

    Report date 2024-09-18 · 0001437749-24-029602 · Items 1.01,3.02,9.01

  28. 10-Q · Quarterly report

    Report date 2024-06-30 · 0001437749-24-025952

  29. 8-K · Current report

    Report date 2024-06-27 · 0001437749-24-021407 · Items 8.01

  30. 8-K · Current report

    Report date 2024-06-07 · 0001437749-24-019961 · Items 4.01,9.01

  31. 8-K · Current report

    Report date 2024-05-17 · 0001437749-24-017754 · Items 1.01,3.02,9.01

  32. 10-Q · Quarterly report

    Report date 2024-03-31 · 0001437749-24-017125

  33. 10-K · Annual report

    Report date 2023-12-31 · 0001437749-24-012587

  34. 8-K · Current report

    Report date 2024-04-16 · 0001437749-24-012214 · Items 7.01

  35. SC 13G · Ownership disclosure

    0001437749-24-004098

  36. SC 13G/A · Ownership disclosure

    0001193805-24-000195

  37. SC 13D/A · Ownership disclosure

    0001437749-23-034986

  38. 8-K · Current report

    Report date 2023-12-18 · 0001437749-23-034949 · Items 1.01,3.02,9.01

  39. 10-Q · Quarterly report

    Report date 2023-09-30 · 0001437749-23-032632

  40. 10-Q · Quarterly report

    Report date 2023-06-30 · 0001437749-23-023710

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 7 transaction rows7AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

9 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-05
2026-06-05
JORDEN DAVID EMERSONA · Grant / award
Acquired
Common Stock13245.01.1
2026-05-29
2026-06-02
Pittman Scott M.A · Grant / award
Acquired
Interim Warrant (right to buy)
Derivative security
17450.01.5
2026-05-29
2026-06-02
Pittman Scott M.A · Grant / award
Acquired
Prepayment Restated Warrant (right to buy)
Derivative security
7333.01.5
2026-05-29
2026-06-02
Pittman Scott M.A · Grant / award
Acquired
Second Restated Warrant (right to buy)
Derivative security
17500.01.5
2026-05-29
2026-06-02
Pittman Scott M.D · Disposition to issuer
Disposed
Second Warrant (right to buy)
Derivative security
36750.01.5
2026-05-29
2026-06-02
Pittman Scott M.D · Disposition to issuer
Disposed
Prepayment Warrant (right to buy)
Derivative security
7516.01.5
2026-01-23
2026-06-02 · Amendment
Pittman Scott M.A · Grant / award
Acquired
Prepayment Warrant (right to buy)
Derivative security
7516.01.5
2026-01-23
2026-06-02 · Amendment
Pittman Scott M.A · Grant / award
Acquired
Initial Warrant (right to buy)
Derivative security
30050.01.5
2026-01-23
2026-06-02 · Amendment
Pittman Scott M.A · Grant / award
Acquired
Second Warrant (right to buy)
Derivative security
36750.01.5

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001091596Nuo Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names
  • Nuo Therapeutics, Inc · former SEC name · 2014-11-13 to 2014-12-23
  • CYTOMEDIX INC · former SEC name · 2000-08-14 to 2014-10-08
  • AUTOLOGOUS WOUND THERAPY INC · former SEC name · 2000-04-12 to 2000-04-10
  • AUTOLOGOUS WOUND TRERAPY INC · former SEC name · 1999-12-10 to 2000-03-23

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$1.37M$1.45M
2023-12-31$608.5K$666.8K
2022-12-31$112.2K$128.1K
2021-12-31$0$0
2020-12-31$0$0
2019-12-31$146.2K$190.9K
2018-12-31$1.37M$1.82M
2017-12-31$721.0K$982.2K

Bureau of Labor Statistics · retrieved 2026-09-08 · 9 selected series; gaps remain missing

Explore the CPI history ↗